Get to know our clinical trials
Study of multiple immunotherapy-based treatment combinations in patients with metastatic pancreatic ductal adenocarcinoma
THE PURPOSE OF THIS STUDY IS TO COMPARE THE EFFECTS, GOOD OR BAD, ON THE PATIENT AND ON PANCREATIC CANCER OF COMBINATIONS OF ATIS AND CONVENTIONAL TREATMENT IN ORDER TO FIND OUT WHICH TREATMENT IS BEST. THE ATI COMBINATIONS ARE EXPERIMENTAL DRUG TREATMENTS, WHICH MEANS THAT THEY ARE NOT APPROVED BY THE HEALTH AUTHORITIES FOR THE TREATMENT OF PANCREATIC CANCER.
Technical Summary
- UNBLINDED, MULTICENTER, RANDOMIZED, PHASE IB/II UMBRELLA STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (MORPHEUS-PANCREATIC CANCER)
- Code EudraCT: 2016-004126-42
- Protocol number: WO39608
- Promoter: F. Hoffmann-La Roche Ltd.
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.